What is the ticker symbol for Protagonist Therapeutics?

Protagonist Therapeutics trades under the ticker PTGX on NASDAQ.

What sector does Protagonist Therapeutics operate in?

Protagonist Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PTGX in a portfolio?

PortView shows PTGX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Protagonist Therapeutics (PTGX) Stock Analysis

NASDAQHealthcareBiotechnology

$145.07-0.97%

1-year price historyRange $56.19 – $158.62

52-week range$145.07

$54.50$160.81

What Protagonist Therapeutics does

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Key metrics

Market cap

$9.33B

P/E (TTM)

140.84

EPS (TTM)

$1.03

Beta

1.79

Dividend yield

0.00%

Revenue / share

$4.28

50-day avg

$139.46

200-day avg

$105.12

52-week high

$160.81

52-week low

$54.50

CEO

Dinesh V. Patel

ETFs linked to PTGX

Broad-market and Healthcare sector ETFs an investor holding Protagonist Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how PTGX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze PTGX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Protagonist Therapeutics?: Protagonist Therapeutics trades under the ticker PTGX on NASDAQ.
Which exchange is PTGX listed on?: PTGX is listed on NASDAQ.
What sector does Protagonist Therapeutics operate in?: Protagonist Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze PTGX in a portfolio?: PortView shows PTGX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.